Scarica l'app Stockscreener
9.08
4.13%
0.36
Dopo l'orario di chiusura:
9.08
Precedente Chiudi:
$8.72
Aprire:
$8.8
Volume 24 ore:
204.66K
Relative Volume:
1.84
Capitalizzazione di mercato:
$130.92M
Reddito:
$166.88M
Utile/perdita netta:
$-74.18M
Rapporto P/E:
-1.7909
EPS:
-5.07
Flusso di cassa netto:
$1.14M
1 W Prestazione:
+10.06%
1M Prestazione:
-19.43%
6M Prestazione:
-48.56%
1 anno Prestazione:
-63.69%
Intervallo 1D:
$8.7214
$9.25
Intervallo di 1 settimana:
$7.92
$9.25
Portata 52W:
$7.8701
$26.99
Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
Anika Therapeutics Inc
Settore
Telefono
(781) 457-9000
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Confronta ANIK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.08 | 118.37M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | B. Riley Securities | Buy |
| 2024-11-01 | Reiterato | Barrington Research | Outperform |
| 2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Ripresa | Stephens | Equal-Weight |
| 2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Iniziato | Stephens | Overweight |
| 2021-07-16 | Iniziato | UBS | Neutral |
| 2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy |
| 2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Iniziato | BWS Financial | Sell |
| 2019-09-24 | Reiterato | Barrington Research | Outperform |
| 2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Downgrade | Sidoti | Buy → Neutral |
| 2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Reiterato | Barrington Research | Outperform |
| 2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
How Anika Therapeutics Inc. stock performs during market volatilityWeekly Profit Report & Fast Exit and Entry Strategy Plans - Newser
How to track smart money flows in Anika Therapeutics Inc.CEO Change & Low Risk High Win Rate Stock Picks - Newser
How to manage a losing position in Anika Therapeutics Inc.Earnings Growth Summary & Long-Term Safe Investment Plans - Newser
Chart overlay techniques for tracking Anika Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
How to track smart money flows in Anika Therapeutics Inc. [2025 Trading Recap]Free Entry Point Confirmation Signals - Newser
Lost Money on Anika Therapeutics, Inc. (ANIK)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Can Anika Therapeutics Inc. hit a new high this monthFree Real Time Alerts Based on AI Prediction - Newser
Applying big data sentiment scoring on Anika Therapeutics Inc.2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics - Bluefield Daily Telegraph
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Ongoing Anika Therapeutics, Inc. (ANIK) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Technical analysis overview for Anika Therapeutics Inc. stockTrade Safety Matrix for Conservative Traders - Newser
Lost Money on Anika Therapeutics, Inc. (ANIK)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc.ANIK - PR Newswire
What makes Anika Therapeutics Inc. stock price move sharplyAI Triggered Buy Zone Forecast System - Newser
Applying chart zones and confluence areas to Anika Therapeutics Inc.Free Accurate Technical Trend Reversal Picks - Newser
Why Anika Therapeutics Inc. stock attracts strong analyst attentionROI Focused Watchlist with Trade Confidence - Newser
Tools to assess Anika Therapeutics Inc.’s risk profileHigh Return Trade Roadmap with Setup Filters - Newser
Ongoing Securities Investigation into Anika Therapeutics, Inc. (ANIK)Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Launches Fraud Investigation on Behalf of Anika Therapeutics, Inc. (ANIK) Shareholders - ACCESS Newswire
What’s the recovery path for long term holders of Anika Therapeutics Inc.Risk Managed Watchlist with Breakout Picks - Newser
Combining machine learning predictions for Anika Therapeutics Inc.Price Action Summary and Entry Strategy Guide - Newser
Anika Therapeutics Inc. stock momentum explainedFree Buy Signal Based on Chart Analysis - Newser
Anika Therapeutics shares rise 2.77% after-hours following positive clinical trial results for Hyalofast. - AInvest
ATTENTION ANIK Shareholders: Lost Money on Anika Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Anika Therapeutics: Undervalued HA Platform with 2027 Catalysts - AInvest
Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts (ANIK) - Seeking Alpha
Anika Therapeutics Inc. stock volume spike explainedFree Investment Strategy With Low Risk - Newser
Published on: 2025-08-06 20:31:06 - Newser
Levi & Korsinsky Investigates Anika Therapeutics, Inc. (ANIK) Over Possible Securities Fraud - ACCESS Newswire
Anika Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Anika Therapeutics, Inc. (ANIK) - ACCESS Newswire
Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive - simplywall.st
Published on: 2025-08-05 23:20:00 - Newser
Anika Therapeutics Under Investigation for Securities Fraud and Misleading Investors. - AInvest
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Anika Therapeutics, Inc. (ANIK) - ACCESS Newswire
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
What are Anika Therapeutics Inc. company’s key revenue driversUnlock powerful stock screening for profits - Jammu Links News
What catalysts could drive Anika Therapeutics Inc. stock higher in 2025Maximize portfolio growth with strategic plans - Jammu Links News
Should I hold or sell Anika Therapeutics Inc. stock in 2025Exceptional return forecasts - Jammu Links News
When is Anika Therapeutics Inc. stock expected to show significant growthNavigate market volatility with smart strategies - Jammu Links News
How does Anika Therapeutics Inc. compare to its industry peersGet exclusive market analysis for investors - Jammu Links News
What are the latest earnings results for Anika Therapeutics Inc.Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Anika Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
Bank of New York Mellon Corp Sells 2,175 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) - Defense World
Barrington Research Cuts Anika Therapeutics (NASDAQ:ANIK) Price Target to $15.00 - Defense World
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anika Therapeutics Inc Azioni (ANIK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
| Nunes Anne | SVP, Chief Operations Officer |
Oct 01 '24 |
Option Exercise |
0.00 |
2,491 |
0 |
14,211 |
4.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):